This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals
by Zacks Equity Research
Bausch (BHC) bids to acquire certain assets of Synergy Pharma for $200 million.
Synergy Pharmaceuticals (SGYP) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Synergy Pharma (SGYP) delivered earnings and revenue surprises of -7.69% and -29.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Synergy Pharmaceuticals (SGYP) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Synergy Pharma (SGYP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well.
Is the Options Market Predicting a Spike in Synergy Pharmaceuticals (SGYP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Synergy Pharmaceuticals (SGYP) stock based on the movements in the options market lately.
Synergy Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Synergy Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Are Options Traders Betting on a Big Move in Synergy Pharmaceuticals (SGYP) Stock?
by Zacks Equity Research
Investors in Synergy Pharmaceuticals (SGYP) need to pay close attention to the stock based on moves in the options market lately.
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.
Synergy Pharmaceuticals (SGYP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Synergy Pharma (SGYP) delivered earnings and revenue surprises of 29.41% and 20.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Synergy Pharmaceuticals (SGYP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Synergy Pharmaceuticals (SGYP) stock based on the movements in the options market lately.
Implied Volatility Surging for Synergy Pharmaceuticals (SGYP) Stock Options
by Zacks Equity Research
Investors in Synergy Pharmaceuticals (SGYP) need to pay close attention to the stock based on moves in the options market lately.
Allergan Requests Shareholders to Veto Management Change
by Zacks Equity Research
Allergan (AGN) responds to shareholders stating that it is open to the latter's opinions. However, the company has requested them to vote against appointment of independent chairman.
Implied Volatility Surging for Synergy Pharmaceuticals (SGYP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Synergy Pharmaceuticals (SGYP) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in Synergy Pharmaceuticals (SGYP) Stock
by Zacks Equity Research
Investors in Synergy Pharmaceuticals (SGYP) need to pay close attention to the stock based on moves in the options market lately.
Allergan (AGN) Q4 Earnings Beat on Increase in Botox Sales
by Zacks Equity Research
Allergan (AGN) beats expectations for both earnings and revenues in Q4. A phase III study evaluating Allergan's migraine candidate, ubrogepant meets its co-primary endpoints.
Implied Volatility Surging for Synergy Pharmaceuticals (SGYP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Synergy Pharmaceuticals (SGYP) stock based on the movements in the options market lately.
Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected
by Zacks Equity Research
Allergan (AGN) announces weaker-than-expected sales outlook for 2018. A generic version of Restasis is expected to be launched in Q2.
Allergan to Cut Jobs Amid Loss of Exclusivity for Key Drugs
by Zacks Equity Research
Allergan (AGN) is laying off over 1,000 employees as part of a cost-cutting and restructuring program as it faces potential loss of exclusivity for some of its key products in 2018.
The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Aradigm and Sucampo Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Aradigm and Sucampo Pharmaceuticals
Ironwood Succeeds in Diabetic Hypertension Phase II Study
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) pipeline candidate, IW-1973, reduces blood pressure and improves metabolic parameters in type II diabetes with hypertension patients in a phase IIa study.
Allergan (AGN) Tops Q3 Earnings Estimates, Tweaks 2017 View
by Zacks Equity Research
Allergan (AGN) beat expectations for earnings while delivering in-line revenues in Q3. While the company slightly lowered its sales guidance, it raised the upper end of the earnings guidance.
Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up
by Zacks Equity Research
Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation.
Synergy Pharmaceuticals (SGYP) Surges: Stock Moves 12.1% Higher
by Zacks Equity Research
Synergy Pharmaceuticals (SGYP) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.
Allergan Reports Positive New Data on Irritable Bowl Drug
by Zacks Equity Research
Allergan plc (AGN) has announced positive data from a pooled analysis of two phase III studies, evaluating its marketed drug Viberzi (eluxadoline) for treatment of adults suffering from irritable bowel syndrome with diarrhea (IBS-D).
Allergan's Irritable Bowel Drug Viberzi Approved in Canada
by Zacks Equity Research
Allergan plc (AGN) announced that Health Canada approved Viberzi (eluxadoline) for the treatment of adults suffering with irritable bowel syndrome with diarrhea (IBS-D)